Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype.

Thambisetty M, An Y, Nalls M, Sojkova J, Swaminathan S, Zhou Y, Singleton AB, Wong DF, Ferrucci L, Saykin AJ, Resnick SM; Baltimore Longitudinal Study of Aging and the Alzheimer's Disease Neuroimaging Initiative..

Biol Psychiatry. 2013 Mar 1;73(5):422-8. doi: 10.1016/j.biopsych.2012.08.015.

2.

18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.

Knopman DS, Jack CR Jr, Wiste HJ, Lundt ES, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Roberts RO, Boeve BF, Petersen RC.

Neurobiol Aging. 2014 Sep;35(9):2096-106. doi: 10.1016/j.neurobiolaging.2014.03.006.

3.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative..

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
4.

Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes.

Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P; Alzheimer's Disease Genetics Consortium., Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD.

Arch Neurol. 2010 Dec;67(12):1473-84. doi: 10.1001/archneurol.2010.201. Erratum in: Arch Neurol. 2011 Feb;68(2):159.

5.

CR1 is associated with amyloid plaque burden and age-related cognitive decline.

Chibnik LB, Shulman JM, Leurgans SE, Schneider JA, Wilson RS, Tran D, Aubin C, Buchman AS, Heward CB, Myers AJ, Hardy JA, Huentelman MJ, Corneveaux JJ, Reiman EM, Evans DA, Bennett DA, De Jager PL.

Ann Neurol. 2011 Mar;69(3):560-9. doi: 10.1002/ana.22277.

6.

Alzheimer risk variant CLU and brain function during aging.

Thambisetty M, Beason-Held LL, An Y, Kraut M, Nalls M, Hernandez DG, Singleton AB, Zonderman AB, Ferrucci L, Lovestone S, Resnick SM.

Biol Psychiatry. 2013 Mar 1;73(5):399-405. doi: 10.1016/j.biopsych.2012.05.026.

7.

Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.

Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschläger A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A.

Neurology. 2009 Apr 28;72(17):1487-94. doi: 10.1212/WNL.0b013e3181a2e8d0.

PMID:
19339712
8.

Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals.

Thambisetty M, Tripaldi R, Riddoch-Contreras J, Hye A, An Y, Campbell J, Sojkova J, Kinsey A, Lynham S, Zhou Y, Ferrucci L, Wong DF, Lovestone S, Resnick SM.

J Alzheimers Dis. 2010;22(4):1099-109. doi: 10.3233/JAD-2010-101350.

9.

Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele.

Langbaum JB, Chen K, Caselli RJ, Lee W, Reschke C, Bandy D, Alexander GE, Burns CM, Kaszniak AW, Reeder SA, Corneveaux JJ, Allen AN, Pruzin J, Huentelman MJ, Fleisher AS, Reiman EM.

Arch Neurol. 2010 Apr;67(4):462-8. doi: 10.1001/archneurol.2010.30.

10.

Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.

Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN.

Am J Pathol. 1996 Jun;148(6):2083-95.

11.

Gene-environment interactions: lifetime cognitive activity, APOE genotype, and β-amyloid burden.

Wirth M, Villeneuve S, La Joie R, Marks SM, Jagust WJ.

J Neurosci. 2014 Jun 18;34(25):8612-7. doi: 10.1523/JNEUROSCI.4612-13.2014.

12.

CR1 and the "vanishing amyloid" hypothesis of Alzheimer's disease.

Gandy S, Haroutunian V, DeKosky ST, Sano M, Schadt EE.

Biol Psychiatry. 2013 Mar 1;73(5):393-5. doi: 10.1016/j.biopsych.2013.01.013. No abstract available.

13.

Beta-amyloid associated differential effects of APOE ε4 on brain metabolism in cognitively normal elderly.

Yi D, Lee DY, Sohn BK, Choe YM, Seo EH, Byun MS, Woo JI.

Am J Geriatr Psychiatry. 2014 Oct;22(10):961-70. doi: 10.1016/j.jagp.2013.12.173.

PMID:
24495404
14.

Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.

Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, Rentz DM, Johnson KA, Sperling RA; Alzheimer's Disease Neuroimaging Initiative.; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing.; Harvard Aging Brain Study..

Neurology. 2014 May 20;82(20):1760-7. doi: 10.1212/WNL.0000000000000431.

15.

Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.

Resnick SM, Bilgel M, Moghekar A, An Y, Cai Q, Wang MC, Thambisetty M, Prince JL, Zhou Y, Soldan A, Wong DF, O'Brien RJ, Ferrucci L, Albert MS.

Neurobiol Aging. 2015 Aug;36(8):2333-9. doi: 10.1016/j.neurobiolaging.2015.04.001.

16.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.

PMID:
15522251
17.

Genetic variation at CR1 increases risk of cerebral amyloid angiopathy.

Biffi A, Shulman JM, Jagiella JM, Cortellini L, Ayres AM, Schwab K, Brown DL, Silliman SL, Selim M, Worrall BB, Meschia JF, Slowik A, De Jager PL, Greenberg SM, Schneider JA, Bennett DA, Rosand J.

Neurology. 2012 Jan 31;78(5):334-41. doi: 10.1212/WNL.0b013e3182452b40.

18.

Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.

Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Tian J, Shi J, Stopford C, Julien C, Thompson J, Payton A, Thaker U, Hayes AJ, Iwatsubo T, Pickering-Brown SM, Pendleton N, Horan MA, Burns A, Purandare N, Lendon CL, Neary D, Snowden JS, Mann DM.

J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):515-7.

19.

Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease.

Zhang Q, Yu JT, Zhu QX, Zhang W, Wu ZC, Miao D, Tan L.

Brain Res. 2010 Aug 12;1348:216-21. doi: 10.1016/j.brainres.2010.06.018.

PMID:
20558149
20.

Missense variants in CR1 are associated with increased risk of Alzheimer' disease in Han Chinese.

Ma XY, Yu JT, Tan MS, Sun FR, Miao D, Tan L.

Neurobiol Aging. 2014 Feb;35(2):443.e17-21. doi: 10.1016/j.neurobiolaging.2013.08.009.

PMID:
24018213
Items per page

Supplemental Content

Support Center